EPHA3 and idiopathic pulmonary fibrosis: We observed a reduced EPHA3, a mesenchymal marker, after the treatment with nintedanib and D + Q in normal senescent lung fibroblasts, while the same effect was not observed in IPF cells with any treatment (Fig. 4c).